| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M E Doyle, J M Ega. Glucagon-like peptide-1. Recent progress in hormone research. vol 56. 2001-04-26. PMID:11237222. |
thus, the actions of glp-1 on the beta-cell are complex, with possible benefits to the diabetic patient that extend beyond a simple glucose-dependent increase in insulin secretion. |
2001-04-26 |
2023-08-12 |
mouse |
| R Ritzel, M Schulte, N Pørksen, M S Nauck, J J Holst, C Juhl, W März, O Schmitz, W H Schmiegel, M A Nauc. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes. vol 50. issue 4. 2001-04-19. PMID:11289042. |
effects of glp-1 on secretory mechanisms in type 2 diabetic patients and subjects with impaired glucose tolerance (igt) known to have impaired pulsatile release of insulin have not yet been studied. |
2001-04-19 |
2023-08-12 |
human |
| R Ritzel, M Schulte, N Pørksen, M S Nauck, J J Holst, C Juhl, W März, O Schmitz, W H Schmiegel, M A Nauc. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes. vol 50. issue 4. 2001-04-19. PMID:11289042. |
in type 2 diabetic patients, exogenous glp-1 at approximately 90 pmol/l improved plasma glucose concentrations (6.4+/-2.1 mmol/l vs. placebo 9.8+/-4.1 mmol/l, p = 0.0005) and significantly increased mean insulin burst mass (by 68%, p = 0.007) and amplitude (by 59%, p = 0.006; deconvolution analysis). |
2001-04-19 |
2023-08-12 |
human |
| R Ritzel, M Schulte, N Pørksen, M S Nauck, J J Holst, C Juhl, W März, O Schmitz, W H Schmiegel, M A Nauc. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes. vol 50. issue 4. 2001-04-19. PMID:11289042. |
by deconvolution analysis, insulin secretory burst frequency was not affected by glp-1 in either type 2 diabetic patients (p = 0.15) or igt subjects (p = 0.76). |
2001-04-19 |
2023-08-12 |
human |
| R Ritzel, M Schulte, N Pørksen, M S Nauck, J J Holst, C Juhl, W März, O Schmitz, W H Schmiegel, M A Nauc. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes. vol 50. issue 4. 2001-04-19. PMID:11289042. |
however, by both autocorrelation and spectral analysis, glp-1 prolonged the period (lag time) between subsequent maxima of insulin concentrations significantly from approximately 9 to approximately 13 min in both type 2 diabetic patients and igt subjects. |
2001-04-19 |
2023-08-12 |
human |
| R Ritzel, M Schulte, N Pørksen, M S Nauck, J J Holst, C Juhl, W März, O Schmitz, W H Schmiegel, M A Nauc. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes. vol 50. issue 4. 2001-04-19. PMID:11289042. |
in conclusion, intravenous glp-1 reduces plasma glucose in type 2 diabetic patients and improves the oscillatory secretion pattern by amplifying insulin secretory burst mass, whereas the oscillatory period determined by autocorrelation and spectral analysis is significantly prolonged. |
2001-04-19 |
2023-08-12 |
human |
| R Ritzel, M Schulte, N Pørksen, M S Nauck, J J Holst, C Juhl, W März, O Schmitz, W H Schmiegel, M A Nauc. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes. vol 50. issue 4. 2001-04-19. PMID:11289042. |
together, these results suggest a normalization of the pulsatile pattern of insulin secretion by glp-1, which supports the future therapeutic use of glp-1-derived agents. |
2001-04-19 |
2023-08-12 |
human |
| H Hui, C Wright, R Perfett. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes. vol 50. issue 4. 2001-04-19. PMID:11289043. |
whether the antidiabetic properties of glp-1 are exclusively due to its insulin secretory activity remains to be determined. |
2001-04-19 |
2023-08-12 |
human |
| H Hui, C Wright, R Perfett. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes. vol 50. issue 4. 2001-04-19. PMID:11289043. |
differentiation of arip cells by exposure to human glp-1 occurs in a time- and dose-dependent manner, and this is associated with an increase in idx-1 and insulin mrna levels. |
2001-04-19 |
2023-08-12 |
human |
| H Hui, C Wright, R Perfett. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes. vol 50. issue 4. 2001-04-19. PMID:11289043. |
interestingly, panc-1 cells, when stably transfected with human idx-1, gained responsiveness to glp-1 and were able to differentiate into beta-cells, as determined by facs analysis, insulin gene expression, intracellular insulin content, and insulin accumulation in the culture medium. |
2001-04-19 |
2023-08-12 |
human |
| A S Rocca, J LaGreca, J Kalitsky, P L Brubake. Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1. Endocrinology. vol 142. issue 3. 2001-04-12. PMID:11181530. |
tissue levels of glp-1 and plasma insulin and glucagon levels were not different between the two groups. |
2001-04-12 |
2023-08-12 |
rat |
| D M Kemp, J F Habene. Insulinotropic hormone glucagon-like peptide 1 (GLP-1) activation of insulin gene promoter inhibited by p38 mitogen-activated protein kinase. Endocrinology. vol 142. issue 3. 2001-04-12. PMID:11181533. |
insulinotropic hormone glucagon-like peptide 1 (glp-1) activation of insulin gene promoter inhibited by p38 mitogen-activated protein kinase. |
2001-04-12 |
2023-08-12 |
rat |
| D M Kemp, J F Habene. Insulinotropic hormone glucagon-like peptide 1 (GLP-1) activation of insulin gene promoter inhibited by p38 mitogen-activated protein kinase. Endocrinology. vol 142. issue 3. 2001-04-12. PMID:11181533. |
glucagon-like peptide 1 (glp-1) stimulates insulin gene transcription by intracellular second messenger cascades leading to direct transcription factor activation or to the up-regulation of insulin promoter specific transcription factors. |
2001-04-12 |
2023-08-12 |
rat |
| D M Kemp, J F Habene. Insulinotropic hormone glucagon-like peptide 1 (GLP-1) activation of insulin gene promoter inhibited by p38 mitogen-activated protein kinase. Endocrinology. vol 142. issue 3. 2001-04-12. PMID:11181533. |
in conclusion, these results demonstrate a novel signaling mechanism whereby p38 mapk represses rins1 promoter activity in response to glp-1, suggesting the involvement of a robust regulatory control by p38 mapk in insulin gene expression. |
2001-04-12 |
2023-08-12 |
rat |
| K Beckoff, C G MacIntosh, I M Chapman, J M Wishart, H A Morris, M Horowitz, K L Jone. Effects of glucose supplementation on gastric emptying, blood glucose homeostasis, and appetite in the elderly. American journal of physiology. Regulatory, integrative and comparative physiology. vol 280. issue 2. 2001-04-12. PMID:11208589. |
ge of a drink (15 ml olive oil and 33 g glucose dissolved in 185 ml water), blood glucose, insulin, gastric inhibitory polypeptide (gip) and glucagon-like peptide-1 (glp-1), and appetite (diet diaries, visual analog scales, and food intake at a buffet meal consumed after the ge study) were evaluated twice, after 10 days on a standard or a glucose-supplemented diet (70 g glucose 3 times a day). |
2001-04-12 |
2023-08-12 |
human |
| K Beckoff, C G MacIntosh, I M Chapman, J M Wishart, H A Morris, M Horowitz, K L Jone. Effects of glucose supplementation on gastric emptying, blood glucose homeostasis, and appetite in the elderly. American journal of physiology. Regulatory, integrative and comparative physiology. vol 280. issue 2. 2001-04-12. PMID:11208589. |
glucose supplementation accelerated ge of glucose (p < 0.05), but not oil; there was a trend for an increase in gip (at 15 min, p = 0.06), no change in glp-1, an earlier insulin peak (p < 0.01), and a subsequent reduction in blood glucose (at 75 min, p < 0.01). |
2001-04-12 |
2023-08-12 |
human |
| E Bertin, P Arner, J Bolinder, E Hagström-Tof. Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. The Journal of clinical endocrinology and metabolism. vol 86. issue 3. 2001-04-05. PMID:11238513. |
to avoid confounding effects, such as changes in insulin secretion when perfusing hormones iv, we used the in situ microdialysis to analyze the impact of human glucagon and glp-1 on lipolysis rates and local blood flow. |
2001-04-05 |
2023-08-12 |
human |
| T Vilsbøll, T Krarup, C F Deacon, S Madsbad, J J Hols. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. vol 50. issue 3. 2001-04-05. PMID:11246881. |
the measurement of intact incretin hormones revealed that total as well as intact gip responses were minimally decreased in patients with type 2 diabetes, whereas the late intact glp-1 response was strongly reduced, supporting the hypothesis that an impaired function of glp-1 as a transmitter in the enteroinsular axis contributes to the inappropriate insulin secretion in type 2 diabetes. |
2001-04-05 |
2023-08-12 |
human |
| J H Nielsen, E D Galsgaard, A Møldrup, B N Friedrichsen, N Billestrup, J A Hansen, Y C Lee, C Carlsso. Regulation of beta-cell mass by hormones and growth factors. Diabetes. vol 50 Suppl 1. 2001-04-05. PMID:11272193. |
surprisingly, glucagon-like peptide-1 (glp-1) was recently found to stimulate not only insulin secretion but also beta-cell replication and differentiation, which may present a new perspective in treatment of type 2 diabetes. |
2001-04-05 |
2023-08-12 |
Not clear |
| D J Drucke. Minireview: the glucagon-like peptides. Endocrinology. vol 142. issue 2. 2001-03-29. PMID:11159819. |
glp-1 controls blood glucose following nutrient absorption via stimulation of glucose-dependent insulin secretion, insulin biosynthesis, islet proliferation, and neogenesis and inhibition of glucagon secretion. |
2001-03-29 |
2023-08-12 |
mouse |